Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation

Transplantation

Volumn 68, Issue 9, 1999, Pages 1288-1294

  Kovarik, John M ^e   Kahan, Barry D ^a   Rajagopalan, P R ^b   Bennett, William ^c   Mulloy, Laura L ^d   Gerbeau, Christophe ^e   Hall, Michael L ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING;

EID: 0033571215     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00012     Document Type: Article

References (17)

1. Amlot PL. Clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: Chatenoud L, ed. Monoclonal antibodies in transplantation. New York: Springer, 1995: 53.
2. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
3. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748-56.
4. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
5. Kovarik JM, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701.
6. Nashan B, Moore R, Amlot PL, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
7. Kahan BD, Rajagopalan PR, Hall ML. Reduction in the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation 1999; 67: 276.
8. Mentre F, Kovarik JM, Gerbeau C. Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. J Pharmacokinet Biopharm 1999; 27: 213.
9. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
10. Beal SL, Sheiner LB. NONMEM user's guide. NONMEM Project Group, San Francisco: University of California at San Francisco, 1991.
11. Landaw EM, Disteffano JJ. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 1984; 246: R665.
12. Chambers JM, Cleaveland WS, Meiner B, Tukey PA. Graphical methods for data analysis. London: Wadsworth International Group and Duxbury Press, 1983.
13. Simulect (basiliximab) product monograph. East Hanover, NJ: Novartis Pharmaceuticals Corp., 1998.
14. Solez KM, Axelson RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
15. Kovarik JM, Moore R, Wolf P, et al. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999; 13: 32.
16. Trang JM. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo BL, ed. Protein pharmacokinetics and metabolism. New York: Plenum Press. 1992: 223.
17. Shah VP, Yacobi A, Barr WH, et al. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res 1996; 13: 1590.